|
Lumenis investigated the reported event by contacting the user facility directly.Attempts by emails and phone calls have been made to obtain, patient treatment settings, patient information, patient photo.Customer reported on high energy, wounded patients.The device ga-0005201cn: (b)(6) was installed in the facility on 12/25/2023 and it's on warranty.Service engineer visited the facility and tested the device.He advised: "machine inspection, on-site check that the handpiece cooling is normal, calibrate the energy and test, the machine is running normally at present." device malfunction wasn't the suspected cause of the adverse event.Lumenis clinical expert reviewed provided date and advised: "patient is an asian female of han nationality with skin type 3 that was treated on the forehead for an undisclosed condition with the ipl handpiece of the m22 system.Patient is generally healthy and does not take any medications.Test spot was not performed and subject was treated with a 560nm filter and a fluence of 18j/cm2 divided into 2 pulses each one 4ms with a 30ms delay.Colling was on.Following treatment the area was red and on the following day it appeared black according to the incident report.In this case the user did not perform a test spot in a concealed area as recommended by the manufacturer, in addition the parameters may be aggressive for an initial treatment and the user should consider reducing the fluence, using a triple pulse, extending the pulse duration or increasing the pulse delay when initiating treatment in patients from asian origin with skin type 3.Additional clinical information is required for a more thorough clinical evaluation including the treated condition, history of past treatments and before and after images.Root cause is user error.Skin burn injury due to incorrect user process for selecting treatment parameters.6 - serious injury requiring non-surgical medical treatment." since the injury is serious, this case is reportable to the fda by lumenis.Should additional significant information become available, the complaint record will be updated accordingly and a follow-up medwatch report will be submitted.Based on risk file (b)(4) risk analysis and report for m22 and stellar platform; user not following treatment instructions (par.#22.1.1), can lead to tissue damage, but these risks are within the acceptable limits.The mitigation is "the user manual instruct the user about the treatment flow".
|